Xsolla and Second Dinner Launch New MARVEL SNAP Web Shop to Enhance Player Experience and Rewards
11.6.2025 15:00:00 CEST | Business Wire | Press Release
Xsolla, a leading global video game commerce company, announces the launch of the rebuilt and officially branded Web Shop for MARVEL SNAP, developed by Second Dinner. Powered by Xsolla’s Web Shop for Mobile Games, this next-generation direct-to-player platform delivers a streamlined, rewards-rich experience designed to engage players more deeply while supporting the studio’s long-term LiveOps strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250611293941/en/
(Graphic: Xsolla)
To celebrate the launch, players worldwide can use the global promo code WEBLAUNCH, now live and fully functional, to unlock special offers and exclusive rewards in the new Web Shop. A secure workaround has been successfully implemented to ensure seamless activation and redemption.
The redesigned Web Shop represents an important next chapter for MARVEL SNAP as the studio moves into self-publishing and creates deeper, more direct relationships with its global player base. Built in close collaboration with Xsolla’s Expert Team, the shop focuses on player choice, convenience, and exclusive rewards, all aligned with the visual identity and gameplay cadence fans expect from MARVEL SNAP.
This upgraded experience introduces several new features and launch-specific offerings:
- Fully branded UI consistent with MARVEL SNAP’s in-game look and feel
- Personalized promo code redemption, welcome bundles, and web-exclusive offers
- Integrated LiveOps tools for segmented targeting, timed rewards, and event synchronization
- Reward systems and seasonal pass alignment to drive engagement
- Enhanced analytics and A/B testing for real-time performance optimization
At launch, players can access a set of limited-time offers, including:
- A seasonal Web Shop Milestone Track, where players can earn Web Points with every purchase to unlock bonus rewards, such as exclusive variants
- Boosted Daily Free Claim, granting 200 Credits per day throughout the launch month
- More web-exclusive promotions are coming soon, designed to deliver recurring offers and unique bundles to reward loyal players
“As we took publishing in-house, one of our top priorities was creating more direct ways to connect with our players and deliver value outside the app stores,” said Matt Wyble, Chief Operating Officer at Second Dinner. “Xsolla helped us build a Web Shop that feels native to the SNAP experience while giving us the tools to offer better rewards, smarter promotions, and more meaningful engagement.”
“Second Dinner’s decision to build a branded, global Web Shop reflects what more developers are discovering: direct-to-player commerce isn’t just viable, it’s valuable,” said Chris Hewish, Chief Strategy Officer at Xsolla. “From seamless payments to real-time optimization tools, this collaboration showcases what happens when powerful technology meets passionate game makers.”
Key benefits at launch include support for over 1,000 localized payment methods through Xsolla Pay Station, LiveOps tools, continuous content updates synchronized with in-game events, and a dedicated optimization team to ensure long-term performance.
To explore the MARVEL SNAP Web Shop and redeem your WEBLAUNCH code starting June 11, visit: marvelsnap.com
To learn more about building a branded Web Shop, visit: xsolla.pro/marvel-snap-ws
About Xsolla
Xsolla is a leading global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
About Second Dinner
Second Dinner is an award-winning independent game development studio founded in 2018 by veteran game developers and pioneers in the collectible card game genre. Its debut title, MARVEL SNAP, has earned 18 major awards, including Mobile Game of the Year from both The Game Awards and DICE, Best Strategy Game from IGN, and the prestigious Apple Design Award for Innovation. www.seconddinner.com
About Marvel
MARVEL is one of the world’s most prominent entertainment brands, built on an unparalleled library of iconic characters and stories that have shaped pop culture for 85 years. The MARVEL brand spans entertainment, including film, television, publishing, licensing, games, live events, digital media, and more.
For more information, visit http://marvel.com/. © 2025 MARVEL
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611293941/en/
Contacts
Media Contact
Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom